期刊
EXPERIMENTAL CELL RESEARCH
卷 333, 期 2, 页码 171-177出版社
ELSEVIER INC
DOI: 10.1016/j.yexcr.2014.11.020
关键词
Multiple sclerosis; Idiopathic pulmonary fibrosis; FTY720; Fingolimod; GPCR; LPA; S1P; LPS; Cannabinoids
资金
- Abbott
- Amira Pharmaceuticals
- Biogen-Idec
- Celgene
- GlaxoSmithKline
- Johnson and Johnson
- Merck
- Mitsubishi Tanabe Pharma Corporation
- Novartis
- Ono Pharmaceutical Co.
- Pfizer
- Taisho Pharmaceutical Co.
- National Institutes of Health [MH051699, NS048478, DA019674]
- Human Frontier Science Program
Lysophospholipids (LPs), including lysophosphatidic acid (LPA), sphingosine 1-phospate (S1P), lysophosphatidylinositol (LPI), and lysophosphatidylserine (LysoPS), are bioactive lipids that transduce signals through their specific cell-surface G protein-coupled receptors, LPA(1-6), S1P(1-5), LPI1, and LysoPS(1-3), respectively. These LPs and their receptors have been implicated in both physiological and pathophysiological processes such as autoimmune diseases, neurodegenerative diseases, fibrosis, pain, cancer, inflammation, metabolic syndrome, bone formation, fertility, organismal development, and other effects on most organ systems. Advances in the LP receptor field have enabled the development of novel small molecules targeting LP receptors for several diseases. Most notably, fingolimod (FTY720, Gilenya, Novartis), an S1P receptor modulator, became the first FDA-approved medicine as an orally bioavailable drug for treating relapsing forms of multiple sclerosis. This success is currently being followed by multiple, mechanistically related compounds targeting SIP receptor subtypes, which are in various stages of clinical development. In addition, an LPA(1) antagonist, BMS-986020 (Bristol-Myers Squibb), is in Phase 2 clinical development for treating idiopathic pulmonary fibrosis, as a distinct compound, SAR100842 (Sanofi) for the treatment of systemic sclerosis and related fibrotic diseases. This review summarizes the current state of drug discovery in the LP receptor field. (C) 2014 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据